TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39191745
Drug: BNT162b2 (CC-B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (CC-B)
Study: 39191755
Drug: Vactosertib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vactosertib (200 mg twice daily) in combination with pomalidomide
Study: 39191809
Drug: Inhaled enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled enriched heparin
Study: 39192162
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 400 mg two times daily for 24 weeks
Study: 39192162
Drug: Mesalamine 1
Normalized name: mesalamine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 1 g t.i.d. for 24 weeks (Control)
Study: 39193207
Drug: As-needed albuterol-budesonide
Normalized name: albuterol / budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed albuterol-budesonide 180/160 µg pressurized metered-dose inhaler (pMDI)
Study: 39193463
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) in addition to conventional medication, 12 EA sessions over 6 weeks.
Study: 39193463
Drug: Waiting-list group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list group receiving only conventional medication.
Study: 39193655
Drug: 1 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mcg/kg dexmedetomidine
Study: 39193655
Drug: 0.25 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mcg/kg dexmedetomidine
Study: 39193655
Drug: 0.5 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mcg/kg dexmedetomidine
Study: 39194012
Drug: Internet-delivered exposure-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered exposure-based cognitive behavior therapy (ECBT) for 12 weeks
Study: 39194024
Drug: Watchful waiting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watchful waiting strategy (no antimicrobial administration for ventilator-associated tracheobronchitis, antimicrobials prescribed only for ventilator-associated pneumonia, sepsis, septic shock, or another infectious diagnosis)
Study: 39194024
Drug: Routine antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antimicrobial treatment strategy for seven days
Study: 39194206
Drug: iAST's first
Approvals — FDA: no, EMA: no, PMDA: no
Description: iAST's first three antibiotic recommendations
Study: 39194206
Drug: Doctor's prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doctor's prescribed antibiotics
Study: 39196551
Drug: n-3 LCPUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 LCPUFA (fish oil) 2.4 g per day until 1 week post partum
Study: 39198799
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mcg via HandiHaler
Study: 39199994
Drug: RHB-104 (triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: RHB-104 (triple antimicrobial therapy)
Study: 39202082
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy sessions of goal-directed and task-specific training (30 sessions, 3 per week for 10 weeks)
Study: 39202082
Drug: Usual Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Physical Therapy treatment
Study: 39202581
Drug: Combined Low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Low Dose of Human Chorionic Gonadotropin (HCG) and Clomiphene Citrate (CC)
Study: 39202581
Drug: Continued Clomiphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued Clomiphene Citrate (CC)
Study: 39203915
Drug: Fermented Soybean
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented Soybean (FSB) Supplementation (1 g once daily for 12 weeks)
Study: 39206389
Drug: Semaglutide (GLP-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide (GLP-1 agonist)
Study: 39206547
Drug: Protein cluster
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein cluster with tumor necrosis factor receptor 1
Study: 39206549
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (threshold, 10 g/dL)
Study: 39206549
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (threshold, 7-8 g/dL)
Study: 39207239
Drug: Epinephrine delivered
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine delivered via metered-dose inhalation
Study: 39207239
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of epinephrine
Study: 39207344
Drug: Nontriptan treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontriptan treatments
Study: 39207839
Drug: Inpatient nipple
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient nipple stimulation therapy via an electric breast pump
Study: 39207839
Drug: Immediate synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate synthetic oxytocin infusion without nipple stimulation
Study: 39208489
Drug: Treatment-free observation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-free observation period
Study: 39208836
Drug: Elexacaftor-tezacaftor-ivacaftor (ETI)
Normalized name: ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elexacaftor-tezacaftor-ivacaftor (ETI) treatment
Study: 39209068
Drug: Dupilumab 100/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 100/200 mg every 2 weeks
Study: 39209155
Drug: Leucine intake
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine intake at 7 different levels over a 3-day period after 2 days of preadaptation to adequate protein intake (1.0 g⋅kg)
Study: 39209187
Drug: Vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 10 mg once daily
Study: 39209203
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g gluten per day
Study: 39209203
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g gluten per day
Study: 39209369
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) treatment for 12 weeks
Study: 39209452
Drug: Various immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various immune checkpoint inhibitors with (nab-)paclitaxel and platinum-based chemotherapy (Cohort 2, 48 patients)
Study: 39209452
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment of toripalimab with chemotherapy (Cohort 3, 27 patients)
Study: 39209495
Drug: Low-exchange SBUF
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-exchange SBUF (L-SBUF) during CPB
Study: 39209730
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine plus dexamethasone 0.1 mg/kg (DEX0.1)
Study: 39209730
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine plus dexamethasone 0.05 mg/kg (DEX0.05)
Study: 39209778
Drug: Antihypertensive deprescribing
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive deprescribing
Study: 39209781
Drug: methylprednisolone (62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone (62.5 mg/mL)
Study: 39209782
Drug: Sabatolimab 800
Normalized name: Sabatolimab
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabatolimab 800 mg every 4 weeks plus spartalizumab 400 mg every 4 weeks until unacceptable toxicity, disease progression and/or treatment discontinuation.
Study: 39209823
Drug: mRNA-1273 (50-µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (50-µg booster dose)
Study: 39210194
Drug: Neoadjuvant radio-chemotherapy
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant radio-chemotherapy (Group 1, 25 cases)
Study: 39210194
Drug: No neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neoadjuvant treatment (Group 2, 28 cases)
Study: 39210194
Drug: Neoadjuvant radio-chemotherapy
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant radio-chemotherapy (Group 1)
Study: 39210194
Drug: No neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neoadjuvant treatment (Group 2)
Study: 39210314
Drug: Website with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Website with referrals to HIV care and substance use disorder treatment resources
Study: 39210342
Drug: Shen Que
Normalized name: Ren shen
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shen Que moxibustion (SQM) + IVF treatment
Study: 39210342
Drug: IVF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF treatment alone (Control)
Study: 39211540
Drug: Multichannel tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multichannel tDCS targeting the left DLPFC, 37 sessions of 30 minutes each over 8 weeks (4 weeks daily treatment + 4 weeks taper).
Study: 39211745
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored nutritional guidance from a clinical nutritionist and oral health guidance from a dental hygienist
Study: 39211865
Drug: Navtemadlin (KRT-232)
Normalized name: Navtemadlin
DrugBank: Navtemadlin (DB15299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navtemadlin (KRT-232) 120 mg daily
Study: 39211865
Drug: Navtemadlin (KRT-232)
Normalized name: Navtemadlin
DrugBank: Navtemadlin (DB15299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navtemadlin (KRT-232) 240 mg daily
Study: 39211964
Drug: Intravenous glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucocorticoid (methylprednisolone, 250 mg)
Study: 39212246
Drug: Low-dose digoxin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose digoxin
Study: 39212270
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of RASIs 48 hours prior to surgery (n=1115)
Study: 39212990
Drug: Early antihypertensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antihypertensive treatment (immediate)
Study: 39212990
Drug: Delayed antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antihypertensive treatment (starting on day 8)
Study: 39212990
Drug: Early antihypertensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antihypertensive treatment (immediate) in patients with PAD
Study: 39212990
Drug: Delayed antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antihypertensive treatment (starting on day 8) in patients with PAD
Study: 39212990
Drug: Early antihypertensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antihypertensive treatment (immediate) in patients without PAD
Study: 39212990
Drug: Delayed antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antihypertensive treatment (starting on day 8) in patients without PAD
Study: 39213138
Drug: Cilofexor (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilofexor (100 mg)
Study: 39213138
Drug: Firsocostat (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firsocostat (20 mg)
Study: 39213187
Drug: Interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption of beta-blocker treatment
Study: 39213187
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of beta-blocker treatment
Study: 39213194
Drug: Vutrisiran (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vutrisiran (25 mg) every 12 weeks for up to 36 months
Study: 39213367
Drug: Optilume drug-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optilume drug-coated balloon (DCB)
Study: 39214018
Drug: Standard consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard consolidation chemotherapy (SC)
Study: 39214047
Drug: PF-06952229 monotherapy
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06952229 monotherapy 375 mg, oral b.i.d., 7 days on/7 days off, 28-day cycles (Part 1A)
Study: 39214047
Drug: PF-06952229 monotherapy
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06952229 monotherapy 375 mg
Study: 39214047
Drug: PF-06952229 monotherapy
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06952229 monotherapy
Study: 39214467
Drug: Bepirovirsen 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen 300 mg once weekly for 24 weeks followed by Peg-IFN 180 μg once weekly for up to 24 weeks (Arm 1)
Study: 39214467
Drug: Bepirovirsen 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen 300 mg once weekly for 12 weeks followed by Peg-IFN 180 μg once weekly for up to 24 weeks (Arm 2)
Study: 39214467
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with bepirovirsen followed by Peg-IFN
Study: 39214801
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg or 2.5 mg per label indication) twice daily
Study: 39215063
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of dark chocolate
Study: 39215531
Drug: Sacubitril/valsartan (Sac/Val)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (Sac/Val) therapy
Study: 39215531
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (control)
Study: 39215646
Drug: High-Dose Quadrivalent
Normalized name: Fluzone High-Dose Quadrivalent PF 2020-2021
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Quadrivalent Influenza Vaccine
Study: 39215646
Drug: Standard-Dose Quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Dose Quadrivalent Influenza Vaccine
Study: 39215793
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 160 mg orally daily
Study: 39215972
Drug: Tight potassium
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight potassium control (supplementing if serum potassium concentration fell below 4.5 mEq/L)
Study: 39215972
Drug: Relaxed potassium
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxed potassium control (supplementing if serum potassium concentration fell below 3.6 mEq/L)
Study: 39216096
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of oral anticoagulation
Study: 39216096
Drug: Interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption of oral anticoagulation
Study: 39216092
Drug: Transcatheter mitral-valve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter mitral-valve repair and guideline-recommended medical therapy (device group)
Study: 39216107
Drug: Garetosmab 10
Normalized name: Garetosmab
DrugBank: Garetosmab (DB16379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garetosmab 10 mg/kg every 4 weeks for 28 weeks
Study: 39216478
Drug: ESG401 (Trop2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESG401 (Trop2 antibody-drug conjugate) at a maximum tolerated dose of 16 mg/kg on days 1, 8, and 15 of a 28-day cycle
Study: 39216478
Drug: ESG401 (Trop2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESG401 (Trop2 antibody-drug conjugate) at therapeutically relevant doses
Study: 39217448
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (watchful waiting)
Study: 39217453
Drug: Ertugliflozin 5
Normalized name: ertugliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 5 mg once daily
Study: 39217504
Drug: Zibotentan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan (10 mg daily for 12 weeks)
Study: 39217553
Drug: Semaglutide 1
Normalized name: semaglutide 14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 1 mg once-weekly subcutaneous injection
Study: 39217556
Drug: Aficamten (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aficamten (5-20 mg daily for 24 weeks)
Study: 39217563
Drug: Aficamten (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aficamten (5-20 mg for 24 weeks)
Study: 39217570
Drug: GMRx2 ¼
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMRx2 ¼ dose (telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg)
Study: 39217570
Drug: GMRx2 ½
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMRx2 ½ dose (telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg)
Study: 39217605
Drug: GP IIb/IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP IIb/IIIa inhibitors (eptifibatide or tirofiban)
Study: 39217605
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy without GP IIb/IIIa inhibitors
Study: 39217615
Drug: Atrial fibrillation
Normalized name: Atrial Fibrillation Betapace 80 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial fibrillation screening enhanced by NT-proBNP; NT-proBNP concentrations measured, single-lead ECG registered once if NT-proBNP <125 ng/L, prolonged screening if NT-proBNP ≥125 ng/L.
Study: 39217615
Drug: Low NT-proBNP
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low NT-proBNP group (NT-proBNP <125 ng/L).
Study: 39217809
Drug: Peginterferon beta-1a
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon beta-1a (125 µg subcutaneous every two weeks)
Study: 39217809
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (30 µg intramuscular once a week)
Study: 39218222
Drug: FPG ≤100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG ≤100 mg/dl
Study: 39218222
Drug: FPG >100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG >100 mg/dl
Study: 39218222
Drug: Metabolically active
Normalized name: Viable and metabolically active allogeneic human NIKS keratinocytes and human dermal fibroblasts cellularized layered scaffold
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolically active drugs
Study: 39218235
Drug: Glucocorticoids treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids treatment
Study: 39218777
Drug: Immediate soft-tissue
Normalized name: methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate soft-tissue augmentation (STA) during the same surgical procedure (Control group)
Study: 39218777
Drug: Delayed soft-tissue
Normalized name: methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed soft-tissue augmentation (STA) performed 3 months later (Test group)
Study: 39218875
Drug: Gender-affirming hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gender-affirming hormonal therapy (GAHT) for 12 weeks
Study: 39218935
Drug: Reduced-dose chemotherapy
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose chemotherapy (RDC) followed by blinatumomab for 2 weeks
Study: 39218935
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment regimen (RDC + blinatumomab)
Study: 39219192
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for HCV
Study: 39219492
Drug: Omaveloxolone 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omaveloxolone 150 mg orally once daily on an empty stomach
Study: 39219857
Drug: Intradermal Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Bacillus Calmette-Guérin (BCG) injection
Study: 39220573
Drug: CM310 300
Normalized name: Immunoglobulin G4 [227-proline], anti-(human interleukin 4 receptor subunit α) (human-Mus musculus monoclonal CM310 γ4-chain), disulfide with human-Mus musculus monoclonal CM310 κ-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM310 300 mg subcutaneously every 2 weeks (Q2W) for a total of 12 doses during the double-blind treatment period and 300 mg CM310 Q2W for a total of 14 doses during the maintenance period.
Study: 39220573
Drug: Placebo subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneously every 2 weeks (Q2W) for a total of 12 doses during the double-blind treatment period and placebo Q2W for a total of 14 doses during the maintenance period.
Study: 39221160
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (waiting list, treatment after 27 days)
Study: 39222035
Drug: Flecainide for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide for 3 months (150 mg once daily in a sustained-release dose)
Study: 39222035
Drug: Flecainide for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide for 6 months (150 mg once daily in a sustained-release dose)
Study: 39222035
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (no additional treatment for 6 months)
Study: 39222348
Drug: Prescription Digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription Digital Therapeutics (PDT)